Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Safety and Efficacy of Folic Acid Combined With Atezolizumab and Bevacizumab as First-Line Therapy for Unresectable Hepatocellular Carcinoma: A Prospective, Open-Label, Single-Arm, Phase Ib/II Clinical Trial

NCT07835737 is registered in ClinicalTrials.gov with West China Hospital as lead sponsor.

NCT NCT07835737
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07835737 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Safety and Efficacy of Folic Acid Combined With Atezolizumab and Bevacizumab as First-Line Therapy for Unresectable Hepatocellular Carcinoma: A Prospective, Open-Label, Single-Arm, Phase Ib/II Clinical Trial
Lead sponsor
West China Hospital
Phase
Phase 1/2
Overall status
Not yet recruiting
Start date
October 1, 2026
Completion date
October 1, 2029
Enrollment
78 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

unresectable hepatocellular carcinoma